After ALTTO: I-SPY Will Hold More Clues About pCR Surrogate Endpoint

The pathological complete response surrogate marker has been hailed as the key to getting drugs to market faster with small studies, but came under attack at ASCO with the failed ALTTO breast cancer trial. Co-lead I-SPY investigator Laura Esserman takes a critical look at ALTTO and explains why the jury is still out on pCR; story features an audio clip of Esserman’s interview with “The Pink Sheet.”